Plasma GAS6 predicts mortality risk in acute heart failure patients: insights from the DRAGON-HF trial
Publication in refereed journal
Full Text
View Full-text in CUHK Digital Object Identifier (DOI) DOI for CUHK Users View Full-text in Publisher Website  |
Times Cited
Altmetrics Information
.
Other information
AbstractBackground
Growth arrest-specific 6 (GAS6) is a vitamin K-dependent protein related to inflammation, fibrosis, as well as platelet function. Genetic ablation of GAS6 in mice protects against cardiac hypertrophy and dysfunction. Nonetheless, the association between plasma GAS6 levels and acute heart failure (AHF) patients is still unknown.
Methods
We measured plasma GAS6 concentrations in 1039 patients with AHF who were enrolled in the DRAGON-HF trial (NCT03727828). Mean follow-up of the study was 889 days. The primary endpoint is all-cause death.
Results
In total, there were 195 primary endpoints of all-cause death and 135 secondary endpoints of cardiovascular death during the mean follow-up duration of 889 days. The higher levels of GAS6 were associated with higher rates of all-cause and cardiovascular death (P < 0.05). Baseline plasma GAS6 levels were still strongly correlated with clinical outcomes in different models after adjustment for clinical factors and N-terminal pro-brain natriuretic peptide (NT-proBNP, P < 0.05). GAS6 could further distinguish the risks of clinical outcomes based on NT-proBNP measurement.
Conclusion
Elevated plasma GAS6 levels were associated with an increased risk of all-cause and cardiovascular death in patients with AHF.
Growth arrest-specific 6 (GAS6) is a vitamin K-dependent protein related to inflammation, fibrosis, as well as platelet function. Genetic ablation of GAS6 in mice protects against cardiac hypertrophy and dysfunction. Nonetheless, the association between plasma GAS6 levels and acute heart failure (AHF) patients is still unknown.
Methods
We measured plasma GAS6 concentrations in 1039 patients with AHF who were enrolled in the DRAGON-HF trial (NCT03727828). Mean follow-up of the study was 889 days. The primary endpoint is all-cause death.
Results
In total, there were 195 primary endpoints of all-cause death and 135 secondary endpoints of cardiovascular death during the mean follow-up duration of 889 days. The higher levels of GAS6 were associated with higher rates of all-cause and cardiovascular death (P < 0.05). Baseline plasma GAS6 levels were still strongly correlated with clinical outcomes in different models after adjustment for clinical factors and N-terminal pro-brain natriuretic peptide (NT-proBNP, P < 0.05). GAS6 could further distinguish the risks of clinical outcomes based on NT-proBNP measurement.
Conclusion
Elevated plasma GAS6 levels were associated with an increased risk of all-cause and cardiovascular death in patients with AHF.
All Author(s) ListTeng Ma, Rongrong Huang, Yanhua Xu, Yangbo Lv, Yifan Liu, Xin Pan, Jia Dong, Di Gao, Zeyu Wang, Fenglei Zhang, Chunxi Yan, Sang-Bing Ong, Yang Su, Dachun Xu
Journal nameJournal of Translational Medicine
Year2023
Month1
Day12
Volume Number21
Issue Number1
Article number21
ISSN1479-5876
LanguagesEnglish-United States
KeywordsGrowth arrest-specific 6, Acute heart failure, Prognosis, Cohort study, Biomarkers
